Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 9 | 2017 | 300 | 1.120 |
Why?
|
| Uterine Perforation | 1 | 2011 | 3 | 0.380 |
Why?
|
| Uterus | 1 | 2011 | 77 | 0.370 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2005 | 44 | 0.360 |
Why?
|
| Brachytherapy | 1 | 2011 | 79 | 0.360 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 119 | 0.350 |
Why?
|
| Hysterectomy | 4 | 2017 | 64 | 0.280 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2005 | 5 | 0.250 |
Why?
|
| Lymph Nodes | 3 | 2017 | 258 | 0.250 |
Why?
|
| Papanicolaou Test | 1 | 2005 | 54 | 0.240 |
Why?
|
| Vaginal Smears | 1 | 2005 | 79 | 0.240 |
Why?
|
| Lymphatic Vessels | 1 | 2004 | 5 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 468 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2012 | 629 | 0.220 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 194 | 0.200 |
Why?
|
| Ovarian Neoplasms | 3 | 2011 | 267 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2005 | 46 | 0.180 |
Why?
|
| Insulin-Like Growth Factor II | 3 | 2005 | 52 | 0.180 |
Why?
|
| Uterine Neoplasms | 2 | 2016 | 99 | 0.150 |
Why?
|
| Taxoids | 3 | 2011 | 41 | 0.150 |
Why?
|
| Carboplatin | 3 | 2011 | 59 | 0.150 |
Why?
|
| Endometrial Neoplasms | 2 | 2008 | 69 | 0.130 |
Why?
|
| Adenocarcinoma | 3 | 2009 | 475 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 349 | 0.120 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 91 | 0.110 |
Why?
|
| Female | 16 | 2017 | 38074 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 369 | 0.100 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2008 | 6 | 0.100 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2008 | 9 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 508 | 0.090 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 125 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2011 | 140 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 4848 | 0.090 |
Why?
|
| Prognosis | 4 | 2016 | 2093 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 504 | 0.080 |
Why?
|
| Humans | 16 | 2017 | 68618 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2008 | 113 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2005 | 8 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2005 | 7 | 0.070 |
Why?
|
| Aged | 5 | 2016 | 14862 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2005 | 24 | 0.060 |
Why?
|
| Middle Aged | 6 | 2016 | 21147 | 0.060 |
Why?
|
| Recurrence | 3 | 2011 | 948 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2011 | 2007 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2005 | 122 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2005 | 110 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 800 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1070 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2009 | 125 | 0.050 |
Why?
|
| Adult | 5 | 2016 | 21403 | 0.050 |
Why?
|
| Platinum | 2 | 2011 | 17 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1046 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 981 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 567 | 0.040 |
Why?
|
| Quality of Life | 3 | 2011 | 1515 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1851 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 274 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2016 | 7277 | 0.030 |
Why?
|
| Risk Factors | 1 | 2004 | 5731 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2005 | 7029 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2012 | 149 | 0.030 |
Why?
|
| Microscopy | 1 | 2012 | 64 | 0.030 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2011 | 6 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 23 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 306 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 238 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 714 | 0.020 |
Why?
|
| Body Weight | 1 | 2008 | 554 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 951 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2004 | 14 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 14 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 772 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 848 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 3705 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 446 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 2358 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 507 | 0.010 |
Why?
|
| Survival Rate | 1 | 2004 | 1056 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 5717 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1753 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 1535 | 0.010 |
Why?
|